4,6-dideoxy-alpha-L-xylo-hexopyranosyl-(1->4)-[beta-D-Galp-(1->3)]-D-GlcpNAc

Term ID

CHEBI:148111

Synonyms

4,6-dideoxy-alpha-L-xylo-hexopyranosyl-(1->4)-[beta-D-galactopyranosyl-(1->3)]-2-acetamido-2-deoxy-D-glucopyranose
beta-D-galacto-hexopyranosyl-(1->3)-[4,6-dideoxy-alpha-L-xylo-hexopyranosyl-(1->4)]-2-acetamido-2-deoxy-D-gluco-hexopyranose
Gal(b1-3)[4,6-deoxy-L-xylHex(a1-4)]GlcNAc
N-[(3R,4R,5S,6R)-5-[(2S,3S,4R,6S)-3,4-dihydroxy-6-methyloxan-2-yl]oxy-2-hydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]acetamide

Definition

An amino trisaccharide that is 2-acetamido-2-deoxy-D-glucopyranose in which the hydroxy groups at positions 3 and 4 have been converted into the corresponding β-D-galactopyranosyl and 4,6-dideoxy-α-L-xylo-pyranosyl derivatives, respectively.

References

glygen:G19170MD
glytoucan:G19170MD
kegg.glycan:G08170

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from 4,6-dideoxy-alpha-L-xylo-hexopyranosyl-(1->4)-[beta-D-Galp-(1->3)]-D-GlcpNAc

Phenotype where environments contain 4,6-dideoxy-alpha-L-xylo-hexopyranosyl-(1->4)-[beta-D-Galp-(1->3)]-D-GlcpNAc

Phenotype modified by environments containing 4,6-dideoxy-alpha-L-xylo-hexopyranosyl-(1->4)-[beta-D-Galp-(1->3)]-D-GlcpNAc

Phenotype affecting 4,6-dideoxy-alpha-L-xylo-hexopyranosyl-(1->4)-[beta-D-Galp-(1->3)]-D-GlcpNAc

Human Disease Model